Buscar
Tempest Therapeutics Inc
TPSTAñadir a la lista de seguimiento
0.496USD
-0.037-6.94%
Cierre 10-30 16:00（ET）
8.38MCap. mercado
0.02P/E TTM
Fuera de horario 16:33 (ET)0.502USD-0.002-0.40%
Fuera de horario 16:33 (ET)Acerca de Tempest Therapeutics Inc Compañía
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Perfil de Tempest Therapeutics Inc
Símbolo de cotizaciónTPST
Nombre de la empresaTempest Therapeutics Inc
Fecha de salida a bolsaOct 04, 2012
Director ejecutivo- -
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección2000 Sierra Point Parkway
CiudadBRISBANE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94005
Teléfono14157988589
Sitio Webhttps://www.tempesttx.com/
Símbolo de cotizaciónTPST
Fecha de salida a bolsaOct 04, 2012
Director ejecutivo- -
Ejecutivos de Tempest Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Dr. John David Yee, M.D.
Dr. John David Yee, M.D.
Independent Director
Independent Director
--
--
Mr. William Drake Richey
Mr. William Drake Richey
Independent Director
Independent Director
--
--
Ms. Nancy Freda-Smith, CPA
Ms. Nancy Freda-Smith, CPA
Director
Director
--
--
Constance Ames
Constance Ames
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Tempest Therapeutics Inc?
Los cinco principales accionistas de Tempest Therapeutics Inc son: Dr. Matthew (Matt) Angel, Ph.D.
¿Cuántas instituciones poseen acciones de Tempest Therapeutics Inc (TPST)?
A fecha de 2026Q1, 68 instituciones poseen acciones de Tempest Therapeutics Inc, con un valor de mercado combinado de aproximadamente 4.51M, lo que representa el 31.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 3582210.00.